Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RD14-01 in Advanced Solid Tumors
NCT05638828Phase 1Unknown
- Start
- Dec 2022
- Primary completion
- Dec 2023
- Modality
- CAR-T Cells
01
Overview
Phase 1, open-label, single-arm trial of RD14-01 in solid tumor. Primary endpoints: Dose Limiting Toxicity at 28 days, Maximum Tolerated Dose at 28 days and 1 more. Status: unknown.
02
Drugs
RD14-01
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05638828.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05638828.